Additionally, previous research suggests that post-treatment with Dex could attenuate early brain injury (EBI) induced by subarachnoid hemorrhage (SAH), and that it exerts its protective effect by inhibiting the activation of the TLR4/NF-κB pathway, the release of pro-inflammatory cytokines and the expression of the NLRP3 inflammasome [32]. The gene discussed is TLR4; the disease is subarachnoid hemorrhage.